Perrigo (PRGO) to Release Quarterly Earnings on Wednesday

Perrigo (NYSE:PRGO) is expected to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $0.31 per share and revenue of $1.0134 billion for the quarter. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Perrigo (NYSE:PRGO) last issued its earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the firm earned $0.60 EPS. The business’s revenue was down 7.2% on a year-over-year basis. On average, analysts expect Perrigo to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Perrigo Price Performance

Shares of NYSE PRGO opened at $10.09 on Monday. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -0.77, a price-to-earnings-growth ratio of 1.21 and a beta of 0.51. Perrigo has a twelve month low of $9.23 and a twelve month high of $27.33. The business has a 50 day simple moving average of $10.53 and a 200-day simple moving average of $11.62.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 28th will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 11.5%. The ex-dividend date of this dividend is Friday, August 28th. Perrigo’s payout ratio is currently -8.85%.

Institutional Investors Weigh In On Perrigo

Hedge funds have recently made changes to their positions in the business. UMB Bank n.a. boosted its position in shares of Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares during the period. Geneos Wealth Management Inc. increased its position in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the period. Meeder Asset Management Inc. bought a new stake in Perrigo during the 4th quarter valued at $28,000. Kestra Investment Management LLC raised its stake in Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after acquiring an additional 642 shares in the last quarter. Finally, Danske Bank A S acquired a new position in Perrigo during the 3rd quarter worth $53,000. Institutional investors own 95.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Perrigo presently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.